Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27960179 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL754167 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL27731097 | 0.98 | TP53 (0.47) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL419967 | 0.98 | TP53 (0.50) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL420985 | 0.91 | TP53 (0.42) | TP53FDPSCA1CA2 | |
| SCHEMBL28560310 | 0.89 | TP53 (0.47) | TP53SMPD1GPR84FDPS | |
| SCHEMBL5461425 | 0.86 | TP53 (0.47) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL8372616 | 0.86 | TP53 (0.47) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL3690657 | 0.86 | TP53 (0.47) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL8740084 | 0.84 | TP53 (0.50) | TP53SMPD1GPR84FDPSFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-01-12 | — | — | US | disclosed |
| EP-3100728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9399067-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2429291-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
| US-8835407-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8236782-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2429291-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132711-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2010-11-18 | — | — | US | disclosed |
| US-7115586-B2 | Non-inclusion cyclodextrin complexes | DECODE GENETICS EHF. (IS) | 2006-10-03 | — | — | US | disclosed |
| EP-1443969-A2 | NON-INCLUSION CYCLODEXTRIN COMPLEXES | Decode Genetics EHF (IS) | 2004-08-11 | — | — | EP | disclosed |
| US-20030109492-A1 | Non-inclusion cyclodextrin complexes | DECODE GENETICS EHF. (IS) | 2003-06-12 | — | — | US | disclosed |
| WO-2003033025-A2 | CYCLODEXTRIN COMPLEXES | DECODE GENETICS EHF (IS) | 2003-04-24 | — | — | WO | disclosed |
| US-5472954-A | Combining cyclodextrin with polymer before adding active material | CYCLOPS H.F. (IS) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885SMPD1 138/4885GPR84 2896/4885 |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885SMPD1 138/4885GPR84 2896/4885 |
| US-20030109492-A1 | Non-inclusion cyclodextrin complexes | SI, CNDP2, NONO | TP53 1483/4885SMPD1 1274/4885GPR84 3660/4885 |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885SMPD1 138/4885GPR84 2896/4885 |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | P2RY6, GP6, PFKP | TP53 2392/4885SMPD1 138/4885GPR84 2896/4885 |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885SMPD1 138/4885GPR84 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.